Progression of liver disease in non-alcoholic fatty liver disease: A prospective clinicopathological follow-up study

Journal of Digestive Diseases

Volumn 15, Issue 10, 2014, Pages 545-552

  Chan, Wah Kheong ^a   Ida, Normiha Hilmi ^a   Cheah, Phaik Leng ^a   Goh, Khean Lee ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Disease progression; Histology; NAFLD; NASH; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PROSPECTIVE STUDY; BIOPSY; BLOOD; ENZYME ASSAY; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CLINICAL ENZYME TESTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84911482102     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12175     Document Type: Article

References (19)

1. Chan WK, Goh KL. Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatol Int 2013; 7: 65-71.
2. Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int 2013; 7: 548-554.
3. Chan WK, Tan AT, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Non-alcoholic fatty liver disease in diabetics - prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol 2013; 28: 1375-1383.
4. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
5. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
6. Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis 2007; 8: 58-64.
7. Goddard E. Estimating alcohol consumption from survey data: updated method of converting volumes to units. In: National Statistics Methodological Series No. 37. Newport; ONS, 2007.
8. Chalasani N, Younossi Z, Lavine JE etal.; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-826.
9. Anuurad E, Shiwaku K, Nogi A etal. The new BMI criteria for Asians by the Regional Office for the Western Pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 2003; 45: 335-343.
10. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
11. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
12. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
13. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
14. Hui AY, Wong VW, Chan HL etal. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407-413.
15. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266.
16. Sanyal AJ, Chalasani N, Kowdley KV etal.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
17. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 2007; 17: 63-70.
18. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
19. Ratziu V, Charlotte F, Heurtier A etal.; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.